Russ Conroy

Data from the phase 3 NRG-GY018 trial support the supplemental biologics license application for pembrolizumab plus chemotherapy as a treatment for those with primary advanced or recurrent endometrial cancer.

Findings from the phase 3 TROPION-Lung01 trial support the biologics license application for datopotamab deruxtecan as a treatment for those with advanced nonsquamous non–small cell lung cancer.

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.

Findings from the phase 2 UNICORN trial support osimertinib as a potential treatment option for patients with metastatic non–small cell lung cancer harboring uncommon EGFR mutations.

Data from the phase 3 EV-302 trial support the supplemental biologics license application for enfortumab vedotin plus pembrolizumab for patients with advanced or metastatic urothelial cancer in Japan.

Measurable residual disease–guided ibrutinib plus venetoclax in chronic lymphocytic leukemia appears to be particularly beneficial in patients with unmutated IGHV and specific genetic abnormalities.

The National Comprehensive Cancer Network has issued a category 2A recommendation for the use of goserelin for ovarian function suppression in those with breast cancer.

Data from the phase 3 FLAURA 2 trial support the FDA approval of osimertinib plus chemotherapy for treating patients with EGFR-mutated non–small cell lung cancer.

Data from the phase 3 RATIONALE-315 study support the use of perioperative tislelizumab plus neoadjuvant chemotherapy in resectable stage II to IIIA non–small cell lung cancer.

Findings from a study raise concerns for the outcomes of individuals who experience an adverse financial event prior to a cancer diagnosis.

The FDA is expected to issue a Prescription Drug User Fee Act date for denileukin diftitox in cutaneous T-cell lymphoma within 30 days of accepting the biologics license application resubmission.

Investigators report clinical benefit with sacituzumab govitecan plus pembrolizumab across all prespecified patient subgroups with metastatic urothelial cancer in cohort 3 of the phase 2 TROPHY-U-01 trial.

The FDA set a Prescription Drug User Fee Act date of June 15, 2024 for repotrectinib as a treatment for those with advanced or metastatic solid tumors harboring an NTRK gene fusion.

Results from a phase 2 trial support the safety and tolerability of VGT-309 in patients with suspected lung cancer who undergo standard-of-care surgical resection.

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

Administering pegylated asparaginase continuously to pediatric patients with acute lymphoblastic leukemia appears to be safe without compromising the efficacy of treatment.

HEMO-CAR-T can now proceed with its evaluation as a treatment for those with acute myeloid leukemia as part of a phase 1 trial.

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

Data from the phase 3 MARIPOSA study support the Type II application for amivantamab plus lazertinib as a treatment for those with EGFR-mutated non–small cell lung cancer.

Treatment with repotrectinib in patients with ROS1 fusion–positive non–small cell lung cancer results in mostly low-grade adverse effects in the phase 1/2 TRIDENT-1 trial.

Investigators discontinued the phase 3 ENHANCE-3 study after magrolimab plus azacitidine and venetoclax yielded an increased risk of death in those with acute myeloid leukemia.

Resection can be safely performed in select patients with cT4 non–small cell lung cancer without compromising perioperative survival, according to Neel Chudgar, MD.

Treatment with second-line vepdegestrant in those with advanced breast cancer is currently under evaluation as part of the phase 3 VERITAC-2 trial.

The FDA sets a Prescription Drug User Fee Action date of June 21, 2024 for blinatumomab as a treatment for those with CD19-positive B-cell precursor acute lymphoblastic leukemia.

Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.

Data from the phase 2 NIPU trial support the FDA’s fast track designation for UV1 in combination with nivolumab and ipilimumab as a treatment for those with unresectable pleural malignant mesothelioma.

Screening frequency appears to be a weak risk factor for advanced breast cancer, with obesity in post-menopausal and dense breasts in pre-menopausal patients being more prominent factors.

Investigators are assessing the safety, tolerability, and initial efficacy of BST02 in those with advanced or metastatic liver cancer as part of a phase 1 trial.